entertainment -WSS

entertainment

author：knowledge 2025-10-02 19:38:38 - browse：1

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Medical schools are missing the mark on artificial intelligence

knowledge

WSS

Judge rejects Trump's request to move Stormy Daniels hush

California Joshua trees severely burned in massive wildfire

Climate activists disrupt London Pride march to protest corporate sponsorship

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Medical mystery: When an infection after surgery isn’t what it seems

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

leisure time

entertainment

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

DIEP, the 'gold standard' of breast reconstruction, is under threat

Does Medicare's free annual wellness visit do any good?

Dobbs anniversary: the lost opportunity of abortion as health care

Ending racial health disparities hinges on penalties, political will

Medical leaders decry Supreme Court decision on affirmative action

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

In age of alternative facts, a scholarly course on calling out crap

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

hotspot

Climate activists disrupt London Pride march to protest corporate sponsorship

Indian pharmaceutical industry in denial over drug

Taylor Swift shares sweet moment with Kobe Bryant's daughter Bianka at Eras Tour concert

California Joshua trees severely burned in massive wildfire

Eat, drink, but be wary — 4 foods that interact with medications

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

hotspot

knowledge

entertainment

focus